Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-31 vs PCV21 and PCV20 in Healthy Adults
NCT07284654Phase 3Completed
- Sponsor
- Vaxcyte
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of VAX-31 in pneumococcal disease, sponsored by Vaxcyte. Started Dec 2025; status: completed.
02
Drugs
VAX-31
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07284654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284654.